The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
Open Access
- 11 September 2023
- journal article
- letter
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-3
Abstract
Recently, the Blinding of Trial Statisticians research team, Iflaifel and colleagues, have produced detailed guidance regarding the blinding or unblinding of statisticians in clinical trials, based on substantial mixed-methods work. I wish to comment on the research findings. In particular, I argue that open-label trials, non-drug trials, or non-inferiority trials should not be treated any differently from blinded superiority trials with regards to the risk of bias assessment. Prevention of bias should be the priority for definitive randomised controlled trials, regardless of the precise study design.Keywords
This publication has 7 references indexed in Scilit:
- Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials: a mixed methods studyTrials, 2023
- Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials unitsTrials, 2022
- The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designBMJ, 2020
- A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies2014
- Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic ReviewPLOS ONE, 2010
- Noninferiority trialsTrials, 2000
- Trials to assess equivalence: the importance of rigorous methods: Fig 1BMJ, 1996